Literature DB >> 12393002

Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes.

Ralica Petrova1, Yasuhiko Yamamoto, Katsuhiko Muraki, Hideto Yonekura, Shigeru Sakurai, Takuo Watanabe, Hui Li, Masayoshi Takeuchi, Zenji Makita, Ichiro Kato, Shin Takasawa, Hiroshi Okamoto, Yuji Imaizumi, Hiroshi Yamamoto.   

Abstract

Long-standing diabetes causes cardiovascular complications including direct cardiac muscle weakening known as diabetic cardiomyopathy. This is characterized by disturbances in both cardiac contraction and relaxation, which are maintained by calcium homeostasis in cardiac cells. Our recent in vitro and in vivo studies have shown that advanced glycation endproducts (AGE) account for diabetic vasculopathy through their engagement of the receptor for AGE (RAGE). Here we show that AGE and RAGE may directly affect the myocardial Ca(2+) homeostasis. We created transgenic mice that overexpressed human RAGE in the heart and analyzed the Ca(2+) transients in cultivated cardiac myocytes (CM) from the RAGE-transgenic and non-transgenic control fetuses. RAGE overexpression was found to reduce the systolic and diastolic intracellular calcium concentration ([Ca(2+)](i)). Exposure to AGE caused a significant prolongation of the decay time of [Ca(2+)](i) in CM from control mice, and this response was augmented in CM from the RAGE transgenic mice. The results suggest that the AGE and RAGE could play an active role in the development of diabetes-induced cardiac dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393002     DOI: 10.1006/jmcc.2002.2084

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  43 in total

1.  Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction.

Authors:  Doron Aronson
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

2.  Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.

Authors:  Tina E Brinkley; Xiaoyan Leng; Barbara J Nicklas; Stephen B Kritchevsky; Jingzhong Ding; Dalane W Kitzman; W Gregory Hundley
Journal:  Metabolism       Date:  2017-02-10       Impact factor: 8.694

Review 3.  Diabetic cardiomyopathy: do women differ from men?

Authors:  Jun Ren; Asli F Ceylan-Isik
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

Review 4.  Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.

Authors:  Remi Neviere; Yichi Yu; Lei Wang; Frederic Tessier; Eric Boulanger
Journal:  Glycoconj J       Date:  2016-06-08       Impact factor: 2.916

5.  Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L Firgany
Journal:  J Mol Histol       Date:  2015-06-04       Impact factor: 2.611

Review 6.  Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy.

Authors:  Rokhsana Mortuza; Subrata Chakrabarti
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

7.  Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice.

Authors:  Susan A Marsh; Louis J Dell'Italia; John C Chatham
Journal:  Amino Acids       Date:  2010-07-30       Impact factor: 3.520

8.  Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report.

Authors:  Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Beatriz Paradela-Dobarro; Lilian Grigorian-Shamagian; José M García-Acuña; Pablo Aguiar-Souto; Michel Jacquet-Hervet; María V Reino-Maceiras; Ezequiel Alvarez; José R González-Juanatey
Journal:  Cardiovasc Diabetol       Date:  2012-08-21       Impact factor: 9.951

Review 9.  Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.

Authors:  Susan J Zieman; David A Kass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Expert Rev Mol Med       Date:  2009-03-12       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.